Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 3/20 | 0.62 |
| ▸ | HTR1D | P28221 | 2/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 13/20 | 0.35 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 4/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8199122 | 0.88 | HTR1A (0.66) | HTR1BHTR1DHTR1ADRD2HTR6 | |
| SCHEMBL10123902 | 0.85 | HTR1B (0.63) | HTR1BHTR1DHTR1ADRD2HTR6 | |
| SCHEMBL12004601 | 0.82 | HTR1A (0.59) | HTR1BHTR1DHTR1ADRD2HTR6 | |
| Naratriptan SCHEMBL29403931 | 0.76 | HTR1D (1.00) | HTR1BHTR1DHTR1AHTR6 | |
| Naratriptan SCHEMBL68753 | 0.76 | HTR1D (1.00) | HTR1BHTR1DHTR1AHTR6 | |
| Naratriptan SCHEMBL41527 | 0.76 | HTR1D (0.98) | HTR1BHTR1DHTR1AHTR6 | |
| Naratriptan SCHEMBL30903899 | 0.76 | HTR1D (0.98) | HTR1BHTR1DHTR1AHTR6 | |
| Naratriptan SCHEMBL12803311 | 0.76 | HTR1D (0.98) | HTR1BHTR1DHTR1AHTR6 | |
| Naratriptan SCHEMBL28587084 | 0.76 | HTR1D (0.98) | HTR1BHTR1DHTR1AHTR6 | |
| Naratriptan SCHEMBL41528 | 0.75 | HTR1D (0.96) | HTR1BHTR1DHTR1AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261950-A1 | Compounds that inhibit cholinesterase | ACHE, BCHE, CHAT | HTR1B 799/4885HTR1D 1726/4885HTR1A 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.